ID: MRFR/HC/8950-CR | March 2021 | Region: Global | 124 pages
Global Growth Hormone Deficiency Market is expected to register a CAGR of 4.20% during the assessment period of 2020 to 2027, to reach USD 5,243.3 Million by 2027.
The growth of the Global Growth Hormone Deficiency Market is expected to be driven by the increasing number of individuals suffering from Growth Hormone Deficiency (GHD), rising awareness regarding the effectiveness of growth hormone along with clinical trials focused on the safety and efficacy of GHD, and the changing lifestyle along with the growing prevalence of genetic disorders. However, the high cost of treatment and increasing counterfeit products being used for the treatment are restraining the market growth. On the other hand, the collaboration of major players with small players, coupled with the rise in the innovation marked by prominent players, poses lucrative opportunities for the global growth hormone deficiency market.
Global Growth Hormone Deficiency Market, By Brand, 2019 (%)
Source: MRFR Analysis
Global Growth Hormone Deficiency Market is segmented based on Brand, Application, Distribution Channel, and Route of Administration.
Global Growth Hormone Deficiency Market is classified into brands such as Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and others. The global growth hormone deficiency market, based on application, is segmented into pediatric growth hormone deficiency, Turner syndrome, Idiopathic Short Stature (ISS), small for gestational age, adult growth hormone deficiency, Prader-Willi syndrome, and others. Growth hormone deficiency is an endocrine disorder characterized by low or deficient secretion of growth hormone. The market growth is due to the growing prevalence of GHD, the increasing launch of drugs by prominent market players, and increasing awareness about the disease. Moreover, an increasing engagement of major market players in the development of growth hormone products is likely to drive market growth.
Global Growth Hormone Market, by route of administration, is segmented into subcutaneous, intravenous, and intramuscular. The subcutaneous segment held a major market share of 43.8% in 2019 and, whereas the intramuscular segment was the fastest-growing segment over the review period of 2020 to 2027. The subcutaneous route segment accounted for a market share of 43.8% in 2019 and is expected to exhibit a CAGR of 3.92% during the forecast period. The segment growth is increasing as it leads to a significant rise in growth rates in patients and a low incidence of antibody development. The majority of the GHD drugs are administered through the subcutaneous route of administration. For instance, brands such as Norditropin, Genotropin, Humatrope, Omnitrope, Nutropin, and Saizen are administered subcutaneously. This route of administration, injections, is reported to be less painful and easier to self-administer. It is also the preferred route of administration in children and adults, eventually by means of the easy-to-use pen-type delivery devices (e.g., Novo Nordisk Norditropin FlexPro Pen; Eli Lilly Humatrope Pen). Moreover, the subcutaneous route is highly preferred for chronic growth hormone therapy. These advantages of the subcutaneous route of administration over other routes are propelling the growth of this segment.
Global Growth Hormone Market is segmented by the distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. The hospital pharmacies segment accounted for a major market share of 40.8% in 2019 and is expected to exhibit a CAGR of 3.92% during the assessment period. Recombinant growth hormone is a prescription medication made available only with a prescription of physician.
Western Europe Growth Hormone Deficiency Market Share, By Country, 2019 (%)
Source: MRFR Analysis
Global Growth Hormone Deficiency Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas is divided into North America and Latin America. North America is further categorized into the US and Canada. The Americas spearheaded the market in 2019 and is likely to continue to during the assessment period as well. This is attributed to the factors such as the increasing prevalence of growth hormone deficiency, widening applications of the hormone, and increasing awareness about the effectiveness of the hormone in short stature.
The European growth hormone deficiency market comprises Eastern Europe and Western Europe. Western Europe comprises countries such as Germany, the UK, France, Italy, and Spain. The European market is expected to be the second-largest growth hormone deficiency market. The market growth in this region is attributed to the rising occurrences of growth hormone deficiencies, increasing preference for growth hormones in the treatment of Idiopathic Short Stature (ISS), and rising government expenditure for the healthcare sector.
Asia-Pacific is anticipated to be the fastest-growing market owing to the growing healthcare expenditure and presence of a large patient pool. Growing investments by market players in the region due to the increasing demand are expected to contribute to the growth of the market.
The Middle East & Africa market has increasing healthcare expenditure, rising investments by major market players, and a growing patient pool which is attributing to the regional market growth.
The Prominent Players in the Global Growth Hormone Deficiency Market are Novo Nordisk A/S, Eli Lily and Company, Novartis AG, Merck KGaA, and Pfizer.
Some of the key strategies followed by market players are FDA approvals, joint ventures, acquisitions, expansions, and collaborations.
Global Growth Hormone Deficiency Market, By Brand
Global Growth Hormone Deficiency Market, By Application
Global Growth Hormone Deficiency Market, By Route of Administration
Global Growth Hormone Deficiency Market, By Distribution Channel
Global Growth Hormone Deficiency Market, By Region
Available Additional Customizations
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.